Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Scrip Team
We are delighted to announce the shortlist for the 15th Annual Scrip Awards.
The financing, which brings the total raised by Juvenescence to $165m, comes as longevity R&D programs supported by the company move towards human testing.
The companies plan to use surrogate endpoint data to win approval to challenge Sanofi and Shire for the Fabry disease market.
The results move AstraZeneca closer to challenging AbbVie and Johnson & Johnson’s blockbuster Imbruvica in the blood cancer market.
The partnership gives the German major another potential source of drugs to treat cardiovascular, oncological and gynecological diseases.
The funding comes as the Dutch biotech closes in on a potential conditional approval and closure of its acquisition of CytoSen.